Carrier frequency of two BBS2 mutations in the Ashkenazi population. (28th July 2013)

• Record Type: Journal Article
• Authors: Fedick, A.; Jalas, C.; Abeliovich, D.; Krakinovsky, Y.; Ekstein, J.; Ekstein, A.; Treff, N.R.
• Is Part Of: Clinical genetics. Volume 85:Number 6(2014:Jun.)
• Page Start: 578
• Page End: 582
• Publication Date: 2013-07-28
• Subjects: Medical genetics -- Periodicals; 616.0420
• DOI: 10.1111/cge.12231
• Languages: English
• ISSNs: 0009-9163

Abstract

<abstract abstract-type="main" id="cge12231-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p id="cge12231-para-0001">Bardet–Biedl syndrome (BBS) is known to be caused by numerous mutations that occur in at least 15 of the BBS genes. As the disease follows an autosomal recessive pattern of inheritance, carrier screening can be performed for at‐risk couples, but the number of potential mutation sites to screen can be daunting. Ethnic studies can help to narrow this range by highlighting mutations that are present at higher percentages in certain populations. In this article, the carrier frequency for two mutations that occur in the <italic>BBS2</italic> gene, c.311A&gt;C and c.1895G&gt;C were studied in individuals of Ashkenazi Jewish descent in order to advise on including them in existing mutation panels for this population. Carrier screenings were performed on individuals from the Ashkenazi Jewish population using a combination of TaqMan genotyping assays followed by real‐time polymerase chain reaction (PCR) and allelic discrimination, and allele‐specific PCR confirmed by restriction analysis. The combined results indicated carrier frequencies of 0.473% (±0.0071%) for the c.311A&gt;C mutation and 0.261% (±0.0064%) for the c.1895G&gt;C mutation. On the basis of these frequencies, we believe that the two mutations should be considered for inclusion in screening panels for the Ashkenazi population.</p> </abstract>